Product Description
Hoffmann-La Roche is developing Taselisib as a treatment for breast cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02340221)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02390427 | P1 |
Completed |
Breast Cancer |
2022-12-01 |
|
| Poseidon | P2 |
Completed |
Breast Cancer |
2022-05-01 |
|
| CTR20160894 | P3 |
Active, not recruiting |
Breast Cancer |
None |